{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:04:18Z","timestamp":1785416658641,"version":"3.56.0"},"reference-count":161,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["25-24-01136"],"award-info":[{"award-number":["25-24-01136"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"award":["25-24-01136"],"award-info":[{"award-number":["25-24-01136"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Nucleosides are extensively employed for the development of pharmaceuticals, chemotherapeutic agents, and bioregulators. Background\/Objectives: The introduction of an additional chiral functionality into a carbohydrate or heterocyclic base fragment may increase the selectivity of interactions with nucleos(t)ide-metabolizing enzymes and receptors and, in some cases, lead to more specific physiological activities. Methods: An improvement of the selectivity of nucleoside-based drugs can be achieved either by the chemical modification of a carbohydrate or a base constituent or by a combination of these two approaches. Additionally, stereospecific enzymatic cleavage of nucleos(t)ide prodrugs containing biodegradable substituents can reduce cytotoxicity and enhance bioavailability. Results: A series of enantiomerically pure nucleosides modified at the ribose or heterocyclic base were obtained by chemical and enzymatic methods. Novel antiviral or anticancer active compounds, inhibiting viral or cellular enzymes or activating cellular nucleoside kinases have been found among chemically synthesized derivatives. Some exhibit strengthened \u201cligand\u2013receptor\u201d interaction, acting on receptors of the purinergic signaling system. During recent extensive structure\u2013activity studies, several drugs and their prototypes have been proposed for the treatment of viral infections: the 2\u2032C-fluoromethyl derivative of sofosbuvir (anti-SARS-CoV, preclinical), VV-261 (SFTSV, phase I clinical), balapiravir (dengue, phase I clinical), mericitabine (approved drug for HCV), and lumicitabine (approved drug for RSV and HMPV). Conclusions: Modern literature data within the scope of the present review suggest that direct modification of nucleosides with various chiral functionalities can be considered as an approach to increase their efficacy, specificity and selectivity.<\/jats:p>","DOI":"10.3390\/ph19071131","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:01:28Z","timestamp":1784768488000},"page":"1131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chiral-Modified Nucleoside Analogues: From Bioactivity to Therapeutic Applications"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1572-5990","authenticated-orcid":false,"given":"Anna A.","family":"Kozlova","sequence":"first","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Street 32, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina N.","family":"Borokh","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Street 32, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1451-0717","authenticated-orcid":false,"given":"Vladimir E.","family":"Oslovsky","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Street 32, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5399-4219","authenticated-orcid":false,"given":"Cyril S.","family":"Alexeev","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Street 32, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7624-8801","authenticated-orcid":false,"given":"Mikhail S.","family":"Drenichev","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Street 32, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref_1","unstructured":"Smith, H.J., and Williams, H. (1998). Smith and Williams\u2019 Introduction to the Principles of Drug Design and Action, Harwood Academic Publishers. [3rd ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Clayden, J., Greeves, N., and Warren, S. (2012). Organic Chemistry, Oxford University Press. [2nd ed.].","DOI":"10.1093\/hesc\/9780199270293.001.0001"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aca.2017.03.021","article-title":"Chiral Recognition and Determination of Enantiomeric Excess by Mass Spectrometry: A Review","volume":"968","author":"Yu","year":"2017","journal-title":"Anal. Chim. Acta"},{"key":"ref_4","unstructured":"Mathews, C.K., and Van Holde, K.E. (1996). Biochemistry, Benjamin Cummings PC. [2nd ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ffj.3228","article-title":"Comparison of odour thresholds and odor qualities of the enantiomers of 4-mercapto-2-alkanones and 4-acetylthio-2-alkanones","volume":"30","author":"Wakabayashi","year":"2015","journal-title":"Flavour. Fragr. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1134\/S0026893321040105","article-title":"Antiviral and Antimicrobial Nucleoside Derivatives: Structural Features and Mechanisms of Action","volume":"55","author":"Zenchenko","year":"2021","journal-title":"Mol. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/128_2006_072","article-title":"From Racemates to Single Enantiomers\u2014Chiral Synthetic Drugs over the Last 20 Years","volume":"Volume 269","author":"Sakai","year":"2006","journal-title":"Novel Optical Resolution Technologies"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Food and Drug Administration (1992). FDA\u2019S Policy Statement for the Development of New Stereoisomeric Drugs. Chirality, 4, 338\u2013340.","DOI":"10.1002\/chir.530040513"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Woolf, A., Wexler, P., Bateman, N., Brent, J., Deng, J.-F., Smolinske, S., and Yang, C.-C. (2022). Thalidomide tragedy, 1950s. History of Modern Clinical Toxicology, Academic Press.","DOI":"10.1016\/B978-0-12-822218-8.00058-2"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.59566\/IJBS.2006.2085","article-title":"Chiral Drugs: An Overview","volume":"2","author":"Nguyen","year":"2006","journal-title":"Int. J. Biomed. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/med.20221","article-title":"Transporters That Translocate Nucleosides and Structural Similar Drugs: Structural Requirements for Substrate Recognition","volume":"32","year":"2012","journal-title":"Med. Res. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the Development of Nucleoside and Nucleotide Analogues for Cancer and Viral Diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2040206617738656","article-title":"Nucleoside diphosphate and triphosphate prodrugs\u2014An unsolvable task?","volume":"25","author":"Meier","year":"2017","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.antiviral.2018.11.016","article-title":"The Evolution of Antiviral Nucleoside Analogues: A Review for Chemists and Non-Chemists. Part II: Complex Modifications to the Nucleoside Scaffold","volume":"162","author":"Yates","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1021\/jo01146a023","article-title":"Contributions to the study of marine products. XXXII. The nucleosides of sponges","volume":"16","author":"Bergmann","year":"1951","journal-title":"I. J. Org. Chem."},{"key":"ref_16","first-page":"2349","article-title":"Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells","volume":"40","author":"Plunkett","year":"1980","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","volume":"741","author":"Monteiro","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.antiviral.2006.05.001","article-title":"Synergistic Antiviral Activity of Acyclovir and Vidarabine against Herpes Simplex Virus Types 1 and 2 and Varicella-Zoster Virus","volume":"72","author":"Suzuki","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_19","first-page":"301","article-title":"Conformational analysis of arabinonucleosides and nucleotides A comparison with the ribonucleosides and nucleotides","volume":"564","author":"Yathindra","year":"1979","journal-title":"Biochim. Biophys. Acta (BBA) -Nucleic Acids Protein Synth."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ejmech.2009.10.032","article-title":"Synthesis and in vitro cytostatic activity of new beta-D-arabino furan[1\u2032,2\u2032:4,5]oxazolo- and arabino-pyrimidinone derivatives","volume":"45","author":"Bosc","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jfluchem.2008.06.007","article-title":"Fluorinated Nucleosides: Synthesis and Biological Implication","volume":"129","author":"Liu","year":"2008","journal-title":"J. Fluor. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e202200174","DOI":"10.1002\/tcr.202200174","article-title":"Influence of Sugar Modifications on the Nucleoside Conformation and Oligonucleotide Stability: A Critical Review","volume":"22","author":"Das","year":"2022","journal-title":"Chem. Rec."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10101","DOI":"10.1093\/nar\/gkaa750","article-title":"Synthesis, chirality-dependent conformational and biological properties of siRNAs containing 5\u2032-(R)- and 5\u2032-(S)-C-methyl-guanosine","volume":"48","author":"Mikami","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e02093-18","DOI":"10.1128\/AAC.02093-18","article-title":"Viral RNA-Dependent RNA Polymerase Inhibitor 7-Deaza-2\u2032-C-Methyladenosine Prevents Death in a Mouse Model of West Nile Virus Infection","volume":"63","author":"Eyer","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1021\/jm0502788","article-title":"Design, Synthesis, and Antiviral Activity of 2\u2032-Deoxy-2\u2032-Fluoro-2\u2032-C-Methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication","volume":"48","author":"Clark","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1039\/D5MD00810G","article-title":"Prodrug strategies in developing antiviral nucleoside analogs","volume":"17","author":"Suresh","year":"2026","journal-title":"RSC Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0008-6215(83)88357-8","article-title":"Synthesis and Properties of 3\u2032-C-Methylnucleosides and Their Phosphoric Esters","volume":"124","author":"Mikhailov","year":"1983","journal-title":"Carbohydr. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1021\/jm048944c","article-title":"Antitumor activity of C-Methyl-b-D-ribofuranosyladenine Nucleoside Ribonucleotide Reductase Inhibitors","volume":"48","author":"Franchetti","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1021\/jm800205c","article-title":"Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3\u2019-C-methyladenosine derivatives","volume":"51","author":"Cappellacci","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1349-7006.2004.tb03189.x","article-title":"Antitumor activity of sugar-modified cytosine nucleosides","volume":"95","author":"Matsuda","year":"2004","journal-title":"Cancer Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.ejmech.2011.01.055","article-title":"Synthesis and biological activity of novel N6-substituted and 2, N6-disubstituted adenine ribo-and 3\u2032-C-methyl-ribonucleosides as antitumor agents","volume":"46","author":"Cappellacci","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2009.10.006","article-title":"Early Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV: A Brief History of Stavudine (D4T) and Its Comparison with Other Dideoxynucleosides","volume":"85","author":"Martin","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1021\/jm00345a001","article-title":"Adenosine receptors: Targets for future drugs","volume":"25","author":"Daly","year":"1982","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuropharm.2015.12.001","article-title":"Medicinal Chemistry of Adenosine, P2Y and P2X Receptors","volume":"104","author":"Jacobson","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11033-024-09246-6","article-title":"Therapeutic potency of A1 adenosine receptor antagonists in the treatment of cardiovascular diseases, current status and perspectives","volume":"51","author":"Bahreyni","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0026-895X(24)23035-2","article-title":"Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells","volume":"55","author":"Feoktistov","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1021\/jm0102755","article-title":"Ribose-Modified Nucleosides as Ligands for Adenosine Receptors: Synthesis, Conformational Analysis, and Biological Evaluation of 1\u2019-C-Methyl Adenosine Analogues","volume":"45","author":"Cappellacci","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ballesteros-Y\u00e1\u00f1ez, I., Castillo, C.A., Merighi, S., and Gessi, S. (2018). The Role of Adenosine Receptors in Psychostimulant Addiction. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00985"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.bjp.0703045","article-title":"A2A Adenosine Receptors in Human Peripheral Blood Cells","volume":"129","author":"Gessi","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4049\/jimmunol.1101845","article-title":"Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors","volume":"188","author":"Cekic","year":"2012","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Gao, Z.-G., and Jacobson, K.A. (2019). A2B Adenosine Receptor and Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205139"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0006-2952(03)00153-9","article-title":"N6-Substituted adenosine derivatives: Selectivity, efficacy, and species differences at A3 adenosine receptors","volume":"65","author":"Gao","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/cr0682195","article-title":"Adenosine receptor antagonists: Translating medicinal chemistry and pharmacology into clinical utility","volume":"108","author":"Baraldi","year":"2008","journal-title":"Chem. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/exer.1998.0573","article-title":"Differing roles of adenosine receptor subtypes in retinal ischemia-reperfusion injury in the rat","volume":"68","author":"Li","year":"1999","journal-title":"Exp. Eye Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1167\/iovs.02-1133","article-title":"Effects of adenosine on intraocular pressure, optic nerve head blood flow, and choroidal blood flow in healthy humans","volume":"44","author":"Polska","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.bbagen.2013.01.005","article-title":"Adenosine, adenosine receptors and glaucoma: An updated overview","volume":"1830","author":"Zhong","year":"2013","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/bjp.2008.22","article-title":"Adenosine receptors and asthma","volume":"153","author":"Brown","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11302-011-9244-9","article-title":"Putative Role of the Adenosine A3 Receptor in the Antiproliferative Action of N6-(2-Isopentenyl)Adenosine","volume":"7","author":"Blad","year":"2011","journal-title":"Purinergic Signal."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/978-3-540-89615-9_14","article-title":"Adenosine Receptors and Cancer","volume":"Volume 193","author":"Wilson","year":"2009","journal-title":"Adenosine Receptors in Health and Disease"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1016\/j.bmcl.2007.10.028","article-title":"Structure\u2013activity relationships of adenosine with heterocyclic N6-substituents","volume":"17","author":"Ashton","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1358\/dof.1995.020.07.531583","article-title":"A3-adenosine receptors: Design of selective ligands and therapeutic prospects","volume":"20","author":"Jacobson","year":"1995","journal-title":"Drugs Future"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.crd.0000181621.84565.9d","article-title":"Tecadenoson","volume":"13","author":"Peterman","year":"2005","journal-title":"Cardiol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1517\/13543780802497284","article-title":"A1 adenosine receptor agonists and their potential therapeutic applications","volume":"17","author":"Elzein","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1527-3466.2003.tb00122.x","article-title":"CVT-510: A selective A1 adenosine receptor agonist","volume":"21","author":"Cheung","year":"2003","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wilson, C., and Mustafa, S. (2009). Adenosine Receptors in Health and Disease. Handbook of Experimental Pharmacology, Springer.","DOI":"10.1007\/978-3-540-89615-9"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2174\/0929867330666230420152130","article-title":"Purine nucleosides and analogues bearing chiral substituents: Medicinal chemistry and therapeutic perspective","volume":"31","author":"Drenichev","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0026-895X(25)10559-2","article-title":"A binding site model and structure-activity relationships for the rat A3 adenosine receptor","volume":"45","author":"Melman","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1021\/jm049408n","article-title":"Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists","volume":"48","author":"Cappellacci","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.drudis.2021.02.020","article-title":"Potential and promising anticancer drugs from adenosine and its analogs","volume":"26","author":"Man","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1039\/D1MD00167A","article-title":"Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets","volume":"12","author":"Jacobson","year":"2021","journal-title":"RSC Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1021\/acsomega.8b01237","article-title":"Repurposing of a nucleoside scaffold from adenosine receptor agonists to opioid receptor antagonists","volume":"3","author":"Tosh","year":"2018","journal-title":"ACS Omega"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"113983","DOI":"10.1016\/j.ejmech.2021.113983","article-title":"A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity","volume":"228","author":"Tosh","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/JVI.06620-11","article-title":"In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus Drugs","volume":"86","author":"Andrei","year":"2012","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.idc.2010.07.001","article-title":"Antiviral drug resistance: Mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0006-2952(99)00035-0","article-title":"Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation","volume":"58","author":"Hatse","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/carcin\/bgn198","article-title":"S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis","volume":"29","author":"Leal","year":"2008","journal-title":"Carcinogenesis"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/0006-2952(87)90533-8","article-title":"S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents","volume":"36","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jtbi.2006.09.011","article-title":"Molecular insights of SAH enzyme catalysis and implication for inhibitor design","volume":"244","author":"Wei","year":"2007","journal-title":"J. Theor. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1517\/13543776.9.9.1197","article-title":"Recent advances in S-adenosyl-L-homocysteine hydrolase inhibitors and their potential clinical applications","volume":"9","author":"Yuan","year":"1999","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8535","DOI":"10.1016\/j.tet.2004.06.131","article-title":"Synthesis and biological activities of 5\u2032-ethylenic and acetylenic modified L-nucleosides and isonucleosides","volume":"60","author":"Wang","year":"2004","journal-title":"Tetrahedron"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1021\/jm9905514","article-title":"Monocyclic L-nucleosides with type 1 cytokine-inducing activity","volume":"43","author":"Ramasamy","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"ref_73","first-page":"1097","article-title":"Review of tenofovir-emtricitabine","volume":"3","author":"Masho","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Qi, H., Wang, Z., Song, X., Wang, M., Ding, H., Ye, H., Meng, Z., He, S., He, Y., and Li, L. (2026). Efavirenz 400 mg vs. 600 mg Combined with Lamivudine and Tenofovir in treatment-na\u00efve HIV-infected patients in China: A randomized, multi-centered, controlled trial. Int. J. Infect. Dis., in press.","DOI":"10.1016\/j.ijid.2026.108859"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Zakharenko, A.L., Luzina, O.A., Chepanova, A.A., Dyrkheeva, N.S., Salakhutdinov, N.F., and Lavrik, O.I. (2023). Natural products and their derivatives as inhibitors of the DNA repair enzyme tyrosyl-DNA phosphodiesterase 1. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065781"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.dnarep.2014.03.020","article-title":"Tyrosyl-DNA-Phosphodiesterases (TDP1 and TDP2)","volume":"19","author":"Pommier","year":"2014","journal-title":"DNA Repair"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"11534","DOI":"10.1073\/pnas.93.21.11534","article-title":"A Eukaryotic Enzyme That Can Disjoin Dead-End Covalent Complexes between DNA and Type I Topoisomerases","volume":"93","author":"Yang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.2174\/092986712802002590","article-title":"DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets","volume":"19","author":"Alagoz","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1016\/j.bmc.2016.09.045","article-title":"Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential","volume":"24","author":"Laev","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_80","first-page":"1153","article-title":"Targeting tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA adducts","volume":"2","author":"Brettrager","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/med.21587","article-title":"Dual DNA topoisomerase 1 and tyrosyl-DNA phosphodiesterase 1 inhibition for improved anticancer activity","volume":"39","author":"Zakharenko","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Dyrkheeva, N.S., Chernyshova, I.A., Ivanov, G.A., Porozov, Y.B., Zenchenko, A.A., Oslovsky, V.E., Zakharenko, A.L., Nasyrova, D.I., Likhatskaya, G.N., and Mikhailov, S.N. (2022). In Vitro and In Silico studies of human tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition by stereoisomeric forms of lipophilic nucleosides: The role of carbohydrate stereochemistry in ligand-enzyme interactions. Molecules, 27.","DOI":"10.3390\/molecules27082433"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/AAC.36.11.2423","article-title":"Selective Inhibition of Human Immunodeficiency Viruses by Racemates and Enantiomers of Cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolan-5-Yl]Cytosine","volume":"36","author":"Schinazi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.36.3.672","article-title":"Activities of the Four Optical Isomers of 2\u2019,3\u2019-Dideoxy-3\u2019-Thiacytidine (BCH-189) against Human Immunodeficiency Virus Type 1 in Human Lymphocytes","volume":"36","author":"Schinazi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1128\/AAC.37.4.875","article-title":"Characterization of Human Immunodeficiency Viruses Resistant to Oxathiolane-Cytosine Nucleosides","volume":"37","author":"Schinazi","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Peters, G.J. (2006). L-Nucleosides as Chemotherapeutic Agents. Deoxynucleoside Analogs in Cancer Therapy, Humana Press.","DOI":"10.1007\/978-1-59745-148-2"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1021\/acs.chemrev.6b00209","article-title":"Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs","volume":"116","author":"Shelton","year":"2016","journal-title":"Chem. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Dantsu, Y., Zhang, Y., and Zhang, W. (2022). Advances in therapeutic L-nucleosides and L-nucleic acids with unusual handedness. Genes, 13.","DOI":"10.3390\/genes13010046"},{"key":"ref_89","first-page":"9","article-title":"L-Nucleosides as Chemotherapeutic Agents","volume":"202","author":"Gumina","year":"2001","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003495-199958010-00015","article-title":"Lamivudine: A Review of Its Therapeutic Potential in Chronic Hepatitis B","volume":"58","author":"Jarvis","year":"1999","journal-title":"Drugs"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0166-3542(98)00041-2","article-title":"Recent Advances in L-Nucleosides: Chemistry and Biology","volume":"40","author":"Wang","year":"1998","journal-title":"Antivir. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/mol.66.2.285","article-title":"Synergistic Antitumor Activity of Troxacitabine and Camptothecin in Selected Human Cancer Cell Lines","volume":"66","author":"Kim","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0960-894X(00)00418-2","article-title":"Synthesis and biological evaluation of L-and D-configuration 1, 3-dioxolane 5-azacytosine and 6-azathymine nucleosides","volume":"10","author":"Luo","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1021\/jm9806749","article-title":"Structure\u2212Activity Relationships of L-Dioxolane Uracil Nucleosides as Anti-Epstein Barr Virus Agents","volume":"42","author":"Lin","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1081\/NCN-100002336","article-title":"Anti-HBV Specific \u03b2-L-2\u2019-Deoxynucleosides","volume":"20","author":"Bryant","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1128\/AAC.42.7.1799","article-title":"Metabolism of 2\u2032,3\u2032-Dideoxy-2\u2032,3\u2032-Didehydro-\u03b2-l(\u2212)-5-Fluorocytidine and Its Activity in Combination with Clinically Approved Anti-Human Immunodeficiency Virus \u03b2-d(+) Nucleoside Analogs In Vitro","volume":"42","author":"Dutschman","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm950836q","article-title":"Design and Synthesis of 2\u2032,3\u2032-Dideoxy- 2\u2032,3\u2032-Didehydro-\u03b2-L-Cytidine (\u03b2-L-d4C) and 2\u2032,3\u2032-Dideoxy-2\u2032,3\u2032-Didehydro-\u03b2-L-5-Fluorocytidine (\u03b2-L-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro","volume":"39","author":"Lin","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1016\/j.bmc.2011.05.026","article-title":"Synthesis of enantiomerically pure D-and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation","volume":"19","author":"Park","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1016\/S0040-4020(03)01074-3","article-title":"Synthesis and anti-HIV activity of L-\u03b2-3\u2019-C-cyano-2\u2019,3\u2019-unsaturated nucleosides and L-3\u2019-C-cyano-3\u2019-deoxyribonucleosides","volume":"59","author":"Zhu","year":"2003","journal-title":"Tetrahedron"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.39.4.979","article-title":"Use of 2\u2019-Fluoro-5-Methyl-Beta-L-Arabinofuranosyluracil as a Novel Antiviral Agent for Hepatitis B Virus and Epstein-Barr Virus","volume":"39","author":"Chu","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0006-2952(96)00049-4","article-title":"Inhibition of Epstein-Barr Virus Replication by a Novel l-Nucleoside, 2\u2032-Fluoro-5-Methyl-\u03b2-l-Arabinofuranosyluracil","volume":"51","author":"Yao","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/S0960-894X(98)00599-X","article-title":"Synthesis and Comparative Evaluation of Two Antiviral Agents: \u03b2-L-Fd4C and \u03b2-D-Fd4C","volume":"8","author":"Chen","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1021\/jm980651u","article-title":"Synthesis and Anti-HIV and Anti-HBV Activities of 2\u2019-Fluoro-2\u2019,3\u2019-Unsaturated l -Nucleosides","volume":"42","author":"Lee","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/095632020501600304","article-title":"Characterization of Hepatitis B Virus Inhibition by Novel 2\u2032-Fluoro-2\u2032,3\u2032-Unsaturated Beta-D- and L-Nucleosides","volume":"16","author":"Pai","year":"2005","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1021\/jm010418n","article-title":"Structure\u2212 activity relationships of 2\u2019-fluoro-2\u2019,3\u2019-unsaturated D-nucleosides as anti-HIV-1 agents","volume":"45","author":"Lee","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/0006-2952(93)90058-5","article-title":"Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2\u2032-deoxycytidine kinase","volume":"45","author":"Shewach","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/pro.359","article-title":"Computational model of hepatitis B virus DNA polymerase: Molecular dynamics and docking to understand resistant mutations","volume":"19","author":"Daga","year":"2010","journal-title":"Protein Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/095632029500600601","article-title":"The Effect of Absolute Configuration on the Anti-HIV and Anti-HBV Activity of Nucleoside Analogues","volume":"6","author":"Furman","year":"1995","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00170857","article-title":"Phase I Trial of 1-(2\u2032-Deoxy-2\u2032-Fluoro-1-Beta-D-Arabinofuranosyl)-5-Methyluracil (FMAU) Terminated by Severe Neurologic Toxicity","volume":"7","author":"Abbruzzese","year":"1989","journal-title":"Investig. New Drugs"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0006-2952(97)00598-4","article-title":"Unique Inhibitory Effect of 1-(2\u2032-Deoxy-2\u2032-Fluoro-\u03b2-l-Arabinofuranosyl)-5-Methyluracil 5\u2032-Triphosphate on Epstein-Barr Virus and Human DNA Polymerases","volume":"55","author":"Kukhanova","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1021\/cr1002563","article-title":"L-Pentoses in Biological and Medicinal Applications","volume":"111","author":"Forsman","year":"2011","journal-title":"Chem. Rev."},{"key":"ref_112","unstructured":"(2023, January 06). Tyzeka: Package Insert\/Prescribing Information. Available online: https:\/\/www.drugs.com\/."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic Nucleoside Phosphonates: A Key Class of Antiviral Drugs","volume":"4","author":"Clercq","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","article-title":"Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections","volume":"16","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1021\/jm2001426","article-title":"Tyrosine-Based 1-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]Cytosine and -Adenine ((S)-HPMPC and (S)-HPMPA) Prodrugs: Synthesis, Stability, Antiviral Activity, and in Vivo Transport Studies","volume":"54","author":"Zakharova","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0166-3542(97)00043-0","article-title":"Anti-HIV Activity of Adefovir (PMEA) and PMPA in Combination with Antiretroviral Compounds: In Vitro Analyses","volume":"36","author":"Mulato","year":"1997","journal-title":"Antivir. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1128\/AAC.38.9.2180","article-title":"Inhibitory Effects of Acyclic Nucleoside Phosphonates on Human Hepatitis B Virus and Duck Hepatitis B Virus Infections in Tissue Culture","volume":"38","author":"Heijtink","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/095632029700800610","article-title":"Synthesis, in Vitro Biological Evaluation and Oral Bioavailability of 9-[2-(Phosphonomethoxy)Propyl]Adenine (PMPA) Prodrugs","volume":"8","author":"Arimilli","year":"1997","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1128\/AAC.01152-15","article-title":"In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate","volume":"59","author":"Callebaut","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.antiviral.2006.06.002","article-title":"Antiviral Acyclic Nucleoside Phosphonates Structure Activity Studies","volume":"71","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2165\/00003495-200363150-00006","article-title":"Tenofovir Disoproxil Fumarate","volume":"63","author":"Chapman","year":"2003","journal-title":"Drugs"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir Alafenamide: A Novel Prodrug of Tenofovir for the Treatment of Human Immunodeficiency Virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2018.04.004","article-title":"The Evolution of Nucleoside Analogue Antivirals: A Review for Chemists and Non-Chemists. Part 1: Early Structural Modifications to the Nucleoside Scaffold","volume":"154","author":"Yates","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/acs.jmedchem.0c01717","article-title":"Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents In Vitro and In Vivo","volume":"64","author":"Hao","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejmech.2016.01.036","article-title":"Modification of the Length and Structure of the Linker of N6-Benzyladenosine Modulates Its Selective Antiviral Activity against Enterovirus 71","volume":"111","author":"Drenichev","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ejmech.2014.11.048","article-title":"Chemical Modification of the Plant Isoprenoid Cytokinin N6-Isopentenyladenosine Yields a Selective Inhibitor of Human Enterovirus 71 Replication","volume":"90","author":"Tararov","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1099\/vir.0.2008\/002915-0","article-title":"Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity","volume":"89","author":"Arita","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"8396","DOI":"10.1016\/j.bmc.2010.09.030","article-title":"N6-Alkyladenosines: Synthesis and Evaluation of in Vitro Anticancer Activity","volume":"18","author":"Ottria","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s11101-019-09620-4","article-title":"Anti-cancer activities of cytokinin ribosides","volume":"18","author":"Voller","year":"2019","journal-title":"Phytochem. Rev."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.phytochem.2010.04.018","article-title":"Anticancer activity of natural cytokinins: A structure\u2013activity relationship study","volume":"71","author":"Voller","year":"2010","journal-title":"Phytochemistry"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"127599","DOI":"10.1016\/j.bmcl.2020.127599","article-title":"Structure Activity Relationship of Novel Antiviral Nucleosides against Enterovirus A71","volume":"30","author":"Tosh","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1021\/jo2004617","article-title":"Synthesis of 3-guaninyl-and 3-adeninyl-5-hydroxymethyl-2-pyrrolidinone nucleosides","volume":"76","author":"Saleh","year":"2011","journal-title":"J. Org. Chem."},{"key":"ref_134","first-page":"207","article-title":"Comparative Bioavailability of Acyclovir from Oral Valacyclovir and Acyclovir in Patients Treated for Recurrent Genital Herpes Simplex Virus Infection","volume":"8","author":"Bras","year":"2001","journal-title":"Can. J. Clin. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1600-6143.2008.02220.x","article-title":"Pharmacokinetics of Low and Maintenance Dose Valganciclovir in Kidney Transplant Recipients","volume":"8","author":"Chamberlain","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1469-0691.2000.00014.x","article-title":"Monitoring Plasma Levels of Ganciclovir in AIDS Patients Receiving Oral Ganciclovir as Maintenance Therapy for CMV Retinitis","volume":"6","author":"Piketty","year":"2000","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"105878","DOI":"10.1016\/j.bioorg.2022.105878","article-title":"Synthesis of 2-Chloropurine Ribosides with Chiral Amino Acid Amides at C6 and Their Evaluation as A1 Adenosine Receptor Agonists","volume":"126","author":"Berzina","year":"2022","journal-title":"Bioorg. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Kopl\u016bnait\u0117, M., Butkut\u0117, K., Stankevi\u010di\u016bt\u0117, J., and Me\u0161kys, R. (2024). Exploring the Mutated Kinases for Chemoenzymatic Synthesis of N4-Modified Cytidine Monophosphates. Molecules, 29.","DOI":"10.3390\/molecules29163767"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1566523219666190307094713","article-title":"Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer","volume":"19","author":"Wang","year":"2019","journal-title":"Curr. Gene Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1566523033347426","article-title":"Suicide Gene Therapy Mediated by the Herpes Simplex Virus Thymidine Kinase Gene\/Ganciclovir System: Fifteen Years of Application","volume":"3","author":"Fillat","year":"2003","journal-title":"Curr. Gene Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jgm.1573","article-title":"The Multisubstrate Deoxyribonucleoside Kinase of Drosophila Melanogaster as a Therapeutic Suicide Gene of Breast Cancer Cells","volume":"13","author":"Ma","year":"2011","journal-title":"J. Gene Med."},{"key":"ref_142","unstructured":"Vorbruggen, H., and Ruh-Pohlenz, C. (2001). Handbook of Nucleoside Synthesis, Wiley & Sons."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2174\/1385272819666140714174457","article-title":"Recent Developments in the Synthesis of Substituted Purine Nucleosides and Nucleotides","volume":"18","author":"Kore","year":"2014","journal-title":"Curr. Org. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.mencom.2011.03.001","article-title":"Biologically important nucleosides: Modern trends in biotechnology and application","volume":"21","author":"Mikhailopulo","year":"2011","journal-title":"Mendeleev Commun."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/adsc.201800411","article-title":"Quantitative prediction of yield in transglycosylation reaction catalyzed by nucleoside phosphorylases","volume":"360","author":"Alexeev","year":"2018","journal-title":"Adv. Synth. Catal."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/adsc.201701005","article-title":"Use of nucleoside phosphorylases for the preparation of purine and pyrimidine 2\u2032-deoxynucleosides","volume":"360","author":"Drenichev","year":"2018","journal-title":"Adv. Synth. Catal."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Eletskaya, B.Z., Berzina, M.Y., Fateev, I.V., Kayushin, A.L., Dorofeeva, E.V., Lutonina, O.I., Zorina, E.A., Antonov, K.V., Paramonov, A.S., and Muzyka, I.S. (2023). Enzymatic synthesis of 2-chloropurine arabinonucleosides with chiral amino acid amides at the C6 position and an evaluation of antiproliferative activity in vitro. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076223"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Rabuffetti, M., Bavaro, T., Semproli, R., Cattaneo, G., Massone, M., Morelli, C.F., Speranza, G., and Ubiali, D. (2019). Synthesis of ribavirin, tecadenoson, and cladribine by enzymatic transglycosylation. Catalysts, 9.","DOI":"10.3390\/catal9040355"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e202200140","DOI":"10.1002\/cctc.202200140","article-title":"Enzyme-mediated synthesis of Molnupiravir: Paving the way for the application of biocatalysis in pharmaceutical industry","volume":"14","author":"Cruz","year":"2022","journal-title":"ChemCatChem"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/0006-2952(85)90643-4","article-title":"5-Substituted-2,2\u2032-Anhydrouridines, Potent Inhibitors of Uridine Phosphorylase","volume":"34","author":"Veres","year":"1985","journal-title":"Biochem. Pharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"24746","DOI":"10.1021\/acsomega.0c03348","article-title":"Intramolecular Michael Additions in Uridine Derivatives: Isolation of the Labile 5\u2032O-C6 Cyclonucleoside","volume":"5","author":"Gissot","year":"2020","journal-title":"ACS Omega"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"9811","DOI":"10.1021\/acs.jmedchem.5c00626","article-title":"Design and Development of a Novel Oral 4\u2019-Fluorouridine Double Prodrug VV261 against SFTSV","volume":"68","author":"Cheng","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-025-02567-3","article-title":"Investigation of a clinical trial drug VV261 as a potent antiviral candidate against Chikungunya virus","volume":"11","author":"Zhang","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_154","unstructured":"Peters, G.J. (2006). The cycloSal-nucleotide Delivery System. Development of Chemical Trojan Horses as Antiviral Agents. Deoxynucleoside Analogs in Cancer Therapy, Humana Press."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium (2021). Repurposed antiviral drugs for COVID-19\u2014Interim WHO solidarity trial results. N. Engl. J. Med., 384, 497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1055\/a-2833-6667","article-title":"Acyclic Nucleoside Phosphonates: The Art of the Prodrug","volume":"8","author":"Zhang","year":"2026","journal-title":"Pharm. Front."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1021\/acs.jmedchem.4c02769","article-title":"Discovery of a 2\u2019-\u03b1-Fluoro-2\u2019-\u03b2-C-(fluoromethyl) Purine Nucleotide Prodrug as a Potential Oral Anti-SARS-CoV-2 Agent","volume":"68","author":"Liang","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11030-020-10178-z","article-title":"The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico","volume":"26","author":"Elfiky","year":"2022","journal-title":"Mol. Div."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1016\/j.ejmech.2011.05.051","article-title":"Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of L-3\u2019-azido-2\u2019,3\u2019-dideoxypurine nucleosides","volume":"46","author":"Zhang","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1021\/jo00011a026","article-title":"Synthesis of L-3\u2019-azido-3\u2019-deoxythymidine and its stereoisomers","volume":"56","author":"Wengel","year":"1991","journal-title":"J. Org. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"14046","DOI":"10.1002\/anie.201407130","article-title":"Cyclic-Disulfide-Based Prodrugs for Cytosol-Specific Drug Delivery","volume":"53","author":"Butora","year":"2014","journal-title":"Angew. Chem. Int. Ed."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:07:51Z","timestamp":1784768871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":161,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ph19071131"],"URL":"https:\/\/doi.org\/10.3390\/ph19071131","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}